This medicine was developed for the treatment of late-stage melanoma to cause apoptosis in melanoma cells by interrupting the BRAF/MEK/ERK pathway only in the presence of the common BRAFV600E mutation. The gene discussed is MAP2K7; the disease is melanoma.